Optomed Oyj (OPTOMED) Fair Value & Analysis
Healthcare · FI · Market cap €33.0M
Fair value as of: Jun 25, 2026
Analysis
Optomed Oyj (OPTOMED) currently trades at €1.83, while our model-based Fair Value estimate is €0.3600 — implying the stock looks roughly 80.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software. It develops, manufactures, and sells fundus cameras for ophthalmologists, pediatricians, endocrinologists, neurologists, and primary health care professionals; and provides professional IT consulting services for government institutions. The company also provides camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Aurora AEYE, Optomed Polaris, and Optomed Lumo brand names, as well as OEM cameras under the Volk Optical, Carl Zeiss Meditec, and Topcon brands. The company provides Avenue AI, an AI streamlines eye specialists' work and minimises screening costs; Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases; Avenue Flow, an eyecare management software; and Avenue Telemedicine, a remote analysis solution. In addition, it…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Optomed Oyj (OPTOMED) undervalued?
What is the fair value of OPTOMED?
What is the quality score of OPTOMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.